[ad_1]
The two biotech leaders have embarked on a research project to streamline manufacturing of non-viral CRISPR gene editing components; the goal is to improve the editing efficiency and cell viability of non-viral based cell therapies
PISCATAWAY, NJ and DUBLIN, Sept. 20, 2022 /PRNewswire/ — GenScript USA Inc.the world’s leading life-science research tools and services provider and Avectasa cell engineering technology leader, are partnering to develop an improved non-viral cell therapy manufacturing process. The two companies share a goal of providing their customers with potent, new methods for developing cell therapies that offer an improved safety profile over viral and non -viral vector techniques.
By combining Avectas’ cell engineering technology and know-how with GenScript’s expertise in synthetic long oligo production, the partnership aims to demonstrate a novel and efficient solution for cell therapy manufacturing and to improve editing efficiency and cell viability over traditional delivery methods.
CRISPR-based non-viral gene editing methods have gained popularity among research teams following concerns about the FDA’s recent draft guidance on the use of viruses for gene and cell therapy. GenScript is collaborating with both academic and industry partners in the development of CRISPR non- viral gene editing to enable next-generation gene- and cell-therapy R&D projects.
Intracellular delivery is integral to the generation of engineered ex vivo cell-based therapies, including genome editing approaches. But the limitations of current delivery modalities, both viral and non-viral, led Avectas to develop the non-viral SOLUPORE® cell engineering technology, which enables efficient delivery of cargoes into cells for the development of next-generation therapies.
The…
Full story available on Benzinga.com
[ad_2]
Source link
